次世代シーケンシングによる葉緑体の稀な遺伝子変異の検出

Executive Industry Relevance

Detection of rare mutations in circulating tumor DNA (ctDNA) is critical for early cancer diagnosis, monitoring treatment response, and identifying resistance mechanisms. The ER-Seq method enhances sensitivity and specificity through bidirectional error correction and targeted enrichment, enabling reliable detection of low-frequency variants. This supports preclinical and clinical decision-making by improving the predictive confidence of liquid biopsy applications in oncology drug development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of tumor heterogeneity by detecting low-frequency mutations that may drive therapeutic resistance.
• Operational Value: Provides a reproducible workflow for ctDNA extraction, library preparation, and targeted capture using 1021 kb probes covering >95% of tumor-related driver mutations.

Screening & Assay Development

• Scientific Value: Facilitates assay standardization by distinguishing true mutations from sequencing artifacts via sense/antisense error correction.
• Operational Value: Enables scalable library construction and hybridization-based capture for consistent quantification of rare variants across sample batches.

Translational & Preclinical Research

• Scientific Value: Supports disease-relevant systems by detecting EGFR pT790M and other low-frequency mutations missed by traditional methods due to background noise.
• Operational Value: Ensures continuity from discovery to preclinical validation through a 48-hour workflow compatible with longitudinal monitoring studies.

Pipeline & Workflow Integration

ER-Seq fits within the discovery continuum by enabling hypothesis testing in early discovery, supporting assay readiness in screening, and providing quantitative mutation frequency data for translational research and preclinical validation.

• Discovery Biology: Supports hypothesis testing and pathway clarification by identifying driver mutations in ctDNA at frequencies as low as 1 in 10^7 wild-type nucleotides.
• Screening: Delivers assay readiness through efficient recovery of cfDNA molecules and improved coverage depth (23% higher than traditional methods).
• Analytics: Generates quantitative dependent variable measurements (variant allele frequency) that allow comparison across treatment conditions and time points.
• Translational Research: Connects to preclinical continuity by detecting resistance mutations like EGFR pT790M, informing risk-adjusted advancement decisions.
• Enterprise Reuse: Functions as a reusable capability due to its universal probe design and cost-effective, streamlined protocol requiring only 1-2 days for execution.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing false positives/negatives through bidirectional error correction and background filtering.
• Operational Value: Enhances reproducibility and scalability via standardized bead-based cleanup, adapter ligation, and PCR enrichment steps.
• Strategic Value: Improves go/no-go decisions by enabling early detection of resistance mutations, reducing late-stage biological risk in oncology pipelines.
• Portfolio Impact: Supports risk-adjusted prioritization through accurate quantification of ctDNA dynamics, informing patient stratification and trial design.

Implementation Considerations

• Requires expertise in nucleic acid extraction, library preparation, and hybridization-based capture.
• Depends on access to sonication equipment, thermal cyclers, magnetic racks, and vacuum concentrators.
• Necessitates cross-team standardization of blood draw timing, storage conditions (6–37°C for up to 72 hours), and plasma/cell separation protocols.
• Involves adaptation considerations when applying the 1021 kb probe panel across different tumor types or model systems.
• Includes practical limitations such as the need to avoid cfDNA loss during extraction, library prep, and bead washes to maintain sensitivity.

Biopharma FAQs